Matt, Author at European Medical Journal - Page 27 of 212

Derm 8.1 feature image

Latest Highlights on Biologic Treatments for Psoriasis and Psoriatic Arthritis from EADV 2020

The VOYAGE 1 trial1 was a placebo- and active-controlled Phase III study to evaluate long-term efficacy and safety of the IL-23p19 inhibitor guselkumab…

Derm 8.1 feature image

Bimekizumab Efficacy and Safety in Patients with Moderate-to-Severe Plaque Psoriasis

Psoriasis is a Th17-driven disease, with both IL-17A and IL-17F playing a pivotal role in its pathogenesis.2,3 BKZ is a monoclonal IgG1 antibody…

EADV Congress Interview: Prof Alexander Stratigos

I became involved in dermatology for various reasons, but what really attracted me was the impressive range and diversity of the specialty…

EADV Congress Interview: Asst Prof Asli Bilgic, Prof Dedee Murrell, Prof Marie-Aleth Richard, Assoc Prof Myrto Trakatelli

The skin is visible, accessible to touch, and enables us to discover conditions by examining it…

Editor’s Pick: Managing Chronic Urticaria: Quo Vadis?

Chronic urticaria (CU) is one of the most commonly diagnosed skin conditions. CU is characterised by the presence of recurrent wheals and/or angioedema…

Impaired Mitochondrial and Metabolic Function of Fibroblasts Derived from Patients with Recessive Dystrophic and Junctional Epidermolysis Bullosa

Recessive dystrophic epidermolysis bullosa (RDEB) and junctional EB (JEB) are inherited disorders characterised by fragility and blistering of epithelial…

Management of Plaque Psoriasis: A Review and Comparison of IL-23 Inhibitors

With the recent advancements of biologic therapies that block IL-23, there is increasing need for analysis of which biologics are most efficacious…

Case Report: Suspected Case of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis Overlap Due to Ursodeoxycholic Acid

Stevens–Johnson syndrome and toxic epidermal necrolysis are well-known severe cutaneous adverse reactions, with >100 medications previously implicated…

Looking PHorward to Improving Long-Term Outcomes in Pulmonary Arterial Hypertension

PH encompasses a heterogeneous group of conditions, including PAH (Group 1), PH due to LHD (Group 2), PH due to lung diseases and/or hypoxia…

EMJ 5 [Supplement 1] 2020 Feature Image

The Lung, at the Heart of Pulmonary Arterial Hypertension

The objectives of this symposium were firstly to recognise the difficult diagnostic journey faced by patients with PAH, to learn expert tips on how…